Place of Origin: | Wuhan, China |
---|---|
Brand Name: | Xinzhou |
Certification: | COA,GMP,CQC,SGS |
Model Number: | 1025967-78-5 |
Document: | Product Brochure PDF |
Minimum Order Quantity: | 1box |
Price: | Negotiate |
Packaging Details: | 1kg/Aluminum foil bag |
Delivery Time: | 1-3 work days |
Payment Terms: | T/T advance, Bitcoin ,western union,Bank transfer |
Supply Ability: | 5000boxes per week |
Model NO.: | Lifitegrast | CAS: | 1025967-78-5 |
---|---|---|---|
Molecular Formula: | C29H24Cl2N2O7S | Purity: | 99% |
Appearance: | Powder | Melting Point: | >163°C (dec.) |
Boiling Point: | 811.9±65.0 °C(Predicted) | Desity: | 1.479±0.06 G/cm3(Predicted) |
Molecular Weight: | 615.48 | Storage: | Hygroscopic, -20°C Freezer, Under Inert Atmosphere |
Highlight: | Lifitegrast Raw Powder,Lifitegrast API Intermediates |
99.5% Purity Chemical Lifitegrast Pharmaceutical Powder CAS 1025967-78-5
Intro
Litakast binds to integrin lymphocyte Functional Association Antigen-1 (LFA-1), a cell surface protein found on the surface of white blood cells and blocks interactionofLFA-1 with its associated ligand intracellular adhesion molecule-1 (ICAM-1). ICAM-1 expression in corneal and conjunctival tissues in dry eye disease. The LFA-1/ICAM-1 interaction may promote the formation of an immune synapse, leading to T-cell activation and migration to the target tissue. In vitro studies have shown that human T-cell line lifitegrast may inhibit T-cell adhesion to ICAM-1 and may inhibit the secretion of inflammatory cytokines in human peripheral blood mononuclear cells. The exact mechanism of action of litakast in dry eye disease is unknown.
Indication
Lifitegrast is a leukocyte functional antigen 1 antagonist used for the treatment of dry eye. Lifitegras can bind leukocyte functional antigen 1 (LFA-1) and prevent LFA-1 from binding to its homogandate intercellular adhesion molecule-1 (ICAM-1). ICAM-1 is overexpressed in corneal and conjunctiva tissues of patients with dry eye disease, and LFA-1 binds to ICAM-1 to promote the formation of immune synapses, resulting in T cell activation and migration to target tissues. In vitro studies have shown that Lifitegrast can inhibit the adhesion of T cells to ICAM-1 and also inhibit the secretion of inflammatory cytokines in human peripheral blood mononuclear cells. The exact mechanism by which Lifitegras treats dry eye is unclear.
Product Name | lifitegrast |
Purity | ≥99% |
Colour | White Powder |
CAS NO. | 1025967-78-5 |
Molecular Formula | C29H24Cl2N2O7S |
Molecular Weight | 615.48 |
Storage | Hygroscopic, -20°C Freezer, Under inert atmosphere |
Melting Point | >163°C (dec.) |
Boiling Point | 811.9±65.0 °C(Predicted) |
Desity | 1.479±0.06 g/cm3(Predicted) |
Xingtai Xinzhou Technology Co., LTD.
Xingtai Xinzhou Technology Co., Ltd. was established in 2022 with strong research and development capabilities and superb synthesis technology, as well as advanced quality control measures. Effectively promote the joint venture and cooperation with the major enterprises, manufacturers, with the idea of industrial development to serve the society and the majority of users. We always adhere to the market demand as the orientation, constantly synthesizing new high-tech chemical products and medical intermediates, mainly exported to the United States, India, South Africa, Nigeria and other countries and regions, has a wealth of export experience, to ensure transportation safety, can let each customer as soon as possible to safely receive the goods.